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ABSTRACT
The age-induced deterioration of the organism results in detrimental and ultimately lethal pathologies. The
process of aging itself involves a plethora of different mechanisms that should be subverted concurrently to
delay and/or prevent age-related maladies. We have identified a natural compound, 4,4ʹ-dimethoxychalcone
(DMC), which promotes longevity in yeast, worms and flies, and protects mice from heart injury and liver
toxicity. Interestingly, both the DMC-mediated lifespan extension and the cardioprotection depend on
macroautophagy/autophagy whereas hepatoprotection does not. DMC induces autophagy by inhibiting
specific GATA transcription factors (TFs), independently of the TORC1 kinase pathway. The autophagy-
independent beneficial effects of DMC might involve its antioxidative properties. DMC treatment results in
a phylogenetically conserved, systemic impact on the metabolome, which is most prominently characterized
by changes in cellular amino acid composition. Altogether, DMC exerts multiple, geroprotective effects by
igniting distinct pathways, and thus represents a potential pharmacological agent that delays aging through
multipronged effects.
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The standard approach to fight age-related pathologies (e.g.
metabolic syndrome, neurodegenerative disorders, neoplastic
and cardiovascular disease) consists in treating each of them
separately. However, this concept undervalues the complex
interconnection between these diseases and underestimates the
pliability of the aging process as their common denominator. An
alternative path for prevention or therapy may involve interven-
tions with intrinsic multi-target effects. In that respect, the
permanent or periodic reduction of calorie intake (without mal-
nutrition) has proven effective in promoting health and lifespan
effects that are triggered by different (possibly intertwined)
mechanisms. Among them are the induction of protective
autophagy, the reduction of oxidative stress, anti-inflammatory
effects, and other systemic metabolic adaptations. However,
most individuals are incapable of observing a lifestyle that
involves dietary constraints. This has prompted the search for
drugs that potentially revert the age-associated decline by acti-
vating (some of) the beneficialmetabolic effects of caloric restric-
tion. To date, only a few substances with such potential have
been found, including nicotinamide adenine dinucleotide pre-
cursors, metformin, resveratrol, rapamycin and spermidine.
In our recent work, we identified yet another natural sub-
stance, the flavonoid 4,4′-dimethoxychalcone (DMC), that
possesses the capacity to slow aging [1]. DMC treatment
extends the lifespan of yeast, worms and flies (three estab-
lished aging models) and slows senescence, the age-related
permanent arrest of the cell cycle, in human cell cultures.
Additionally, we demonstrated cardio- and hepatoprotective
effects of intraperitoneally injected DMC in mice. DMC sig-
nificantly reduces the infarction area in the heart tissue caused
by prolonged myocardial ischemia. Moreover, DMC dampens
the ethanol-induced increase of circulating serum GPT/ala-
nine aminotransferase activity, which is a biomarker of liver
damage. In sum, these results show that the health-promoting
effects of DMC are phylogenetically conserved across distinct
species.
Importantly, DMC increases autophagic flux in all tested
organisms, and this autophagy enhancement is causally linked
to most of its protective effects. Upon disruption (or silen-
cing) of specific autophagy-related (ATG) genes, DMC loses
its ability to increase lifespan in yeast, worms and flies.
Moreover, DMC fails to protect mice from myocardial
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ischemia if Atg7 is conditionally ablated in the heart muscle
(Figure 1). However, there are 2 exceptions to this depen-
dency on autophagy. (1) In yeast, the DMC effects only
require autophagy at later time points but not at the early
stage of chronological aging. An explanation might be that
DMC – like many other flavonoids – has antioxidant proper-
ties, which may act independently from autophagy. In yeast,
DMC was only supplied once at the start of the experiment,
and the initial protection may rely on the acute and direct
reduction of oxidative stress. (2) The hepatoprotective effects
of DMC in mice are maintained in whole body Atg4b knock-
out animals (Figure 1); nevertheless, DMC does significantly
promote autophagic flux in the liver. While our data imply
that this induction is merely correlative, we did not explore
whether it may correspond to a non-canonical form of autop-
hagy that would not require Atg4b and/or whether other Atg4
isoforms may be involved. Should that be the case, a causal
relationship between DMC’s pro-autophagic effect in the liver
and hepatoprotection could still be possible. Thus, further
experiments addressing this question are warranted.
Irrespective of additional non-autophagic mechanisms, the
main protective effects of DMC do depend on autophagy.
Thereby, specific GATA transcription factors (TFs) seem cru-
cial. In yeast, deletion of GLN3 (but not other GATA TF
genes) precludes DMC cytoprotection. Similarly, silencing of
specific GATA TFs in nematodes (ELT-1) and human cell
culture (most prominently GATA2) abolish the DMC-
mediated effects. Our data suggest that DMC might function
via inhibition of these specific GATA TFs, because DMC
treatment strongly reduces Gln3 activity in yeast, and results
in a similar metabolomic shift as GLN3 disruption. In line,
gln3 deletion mutants manifest both increased lifespan and
elevated autophagy levels per se during chronological aging.
Beyond the mode of action of DMC, our work poses
a broader question: are GATA TFs general determinants of
aging? Exploring the relevance of GATA TFs in more com-
plex eukaryotic aging will require dissecting which of the
multiple GATA family members contributes to aging, perhaps
acting in a tissue-specific fashion, a possibility that might
render difficult the exploration of this system. In line with
a functional role of GATA TFs during aging, it has been
recently suggested that in Drosophila, the GATA factor srp
(serpent) is involved in a regulatory hub that links dietary
essential amino acids, dietary restriction and longevity.
A further mechanistic finding is that DMC operates inde-
pendently of TORC1 kinase, a master regulator of autophagy,
the inhibition of which has been extensively associated with
longevity. Vice versa, rapamycin (a specific TORC1 inhibitor)
does not require GATA TFs to induce autophagy and to
extend lifespan, at least in yeast. This opens the possibility
to combine TORC1-dependent and -independent interven-
tions with the hope of obtaining even more profound gero-
protective effects. In fact, as a proof of principle, we found
that DMC and rapamycin exert additive cytoprotective effects
in yeast.
Finally, our data reveal that DMC has a major impact on
amino acid metabolism. The proteome of DMC-treated yeast
is characterized by a significant downregulation of proteins
involved in amino acid regulation, but also – although to
a lower extent – of proteins connected to carboxylic acid,
organic acid, amine and nitrogen components. Similarly,
metabolomic analysis of DMC-treated yeast cells as well as
of cardiac and hepatic tissues from mice subjected to intra-
peritoneal DMC treatment show decreased levels of most
amino acids. Although these systemic metabolic changes are
only correlative, they may reflect a general reprogramming
that is essential for DMC-mediated effects, especially in view
of the known influence of amino acid metabolism on aging
and diverse age-related diseases. Of note, amino acid regula-
tion is strongly determined via transcription, and other tran-
scriptional regulators (beyond GATA factors) might be
involved in the metabolic impact of DMC.
In sum, DMC seems to mediate its beneficial effects
through multiple routes, including antioxidative and pro-
autophagic mechanisms as well as other (possibly connected)
systemic metabolic adaptations. This aligns well with the
Figure 1. 4,4ʹ-dimethoxychalcone (DMC) promotes health through autophagy-dependent and -independent effects. DMC treatment results in a characteristic
intracellular response with a number of beneficial effects across species. Autophagy is causal for lifespan extension in yeast, nematodes and fruit flies as well as for
cardioprotection in mice. Per contra, the protective effects of DMC in the liver, where autophagy is also induced upon DMC treatment, do not depend on Atg4b,
suggesting pathways alternative to canonical autophagy. Illustrations adapted from Servier Medical Art, licensed under a CC-BY 3.0 Unported License.
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concept that caloric restriction-like interventions should
involve multi-target effects. In that respect, DMC (or deriva-
tives thereof) may indeed become a valid pharmacological
path for the prevention or treatment of age-related diseases.
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